PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

被引：5
|
作者：
Delea, T. E. [1 ]
Sofrygin, O. [1 ]
Amonkar, M. [2 ]
机构：
[1] PAI, Brookline, MA USA
[2] GlaxoSmithKline Inc, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72194-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a Canadian perspective
    Delea, Thomas E.
    El Ouagari, Khalid
    Karnon, Jon
    Sofrygin, Oleg
    Barghout, Victoria
    ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [32] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Delea, Thomas E.
    El-Ouagari, Khalid
    Karnon, Jonathan
    Sofrygin, Oleg
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (03) : 375 - 387
  • [33] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Thomas E. Delea
    Khalid El-Ouagari
    Jonathan Karnon
    Oleg Sofrygin
    Breast Cancer Research and Treatment, 2008, 108 : 375 - 387
  • [34] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective
    Delea, TE
    Karnon, J
    Thomas, SK
    Barghout, V
    Papo, NL
    Johnston, SRD
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S102 - S102
  • [35] Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).
    Magbanua, Mark Jesus Mendoza
    Savenkov, Oleksandr Oleksandr
    Asmus, Erik
    Ballman, Karla V.
    Scott, Janet H.
    Park, John
    Dickler, Maura N.
    Partridge, Ann H.
    Carey, Lisa A.
    Winer, Eric P.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR plus ) locally advanced/metastatic breast cancer (LABC/MBC).
    Lim, Joline Si Jing
    Wong, Andrea Li Ann
    Ow, Samuel Guan Wei
    Eng, Lim Siew
    Sundar, Raghav
    Chan, Gloria H. J.
    Yadav, Kritika
    Heong, Valerie
    Tan, David Shao Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Yong, Wei-Peng
    Goh, Boon C.
    Lee, Soo-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] COST EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
    Suri, G.
    Mistry, R.
    Young, K. C.
    Hettle, R.
    May, J. R.
    Brixner, D.
    Oderda, G.
    Biskupiak, J.
    Tang, D.
    Bhattacharyya, D.
    Bhattacharyya, S.
    Mishra, D.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [38] Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Finn, Richard S.
    Press, Michael F.
    Dering, Judy
    O'Rourke, Lisa
    Florance, Allison
    Ellis, Catherine
    Martin, Anne-Marie
    Johnston, Stephen
    CLINICAL CANCER RESEARCH, 2014, 20 (03) : 736 - 743
  • [39] Ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative, advanced breast cancer (ABC) who received no prior therapy for advanced disease
    Janni, W.
    Nusch, A.
    Grischke, E. -M
    Marschner, N.
    Wilke, J.
    Decker, T.
    Abenhardt, W.
    Kurbacher, C.
    Overkamp, F.
    Just, M.
    Kuemmel, S.
    Marme, F.
    Xuan, F.
    Miller, M.
    Sonke, G. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 214 - 215
  • [40] The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
    King, Madeleine T.
    Norman, Richard
    Mercieca-Bebber, Rebecca
    Costa, Daniel S. J.
    McTaggart-Cowan, Helen
    Peacock, Stuart
    Janda, Monika
    Mueller, Fabiola
    Viney, Rosalie
    Pickard, Alan Simon
    Cella, David
    VALUE IN HEALTH, 2021, 24 (06) : 862 - 873
12345